ONLY Nobivac® Lyme induces borreliacidal antibodies that target and kill bacteria expressing outer surface protein (Osp) A and ALL OspC variants—delivering more complete coverage and confidence with every dose.1,2 LEARN MORE! The borreliacidal antibodies in Nobivac® Lyme were shown to be effective against Borrelia burgdorferi.* After Nobivac® Lyme vaccination, no B. burgdorferi were found2 No signs of Lyme disease–associated joint abnormalities2 *The tick challenge study was a placebo-controlled trial involving thirty, 8-week-old puppies. Dogs were challenged 3 weeks after second vaccination.2 LEARN MORE! Nobivac® Lyme reliably induces borreliacidal antibodies against OspA and OspC.† Spirochetes killed by Nobivac® Lyme Live, motile spirochetes left by the competition †A blinded study involving 3 randomized groups of five, 9-week-old, laboratory-reared Beagles vaccinated according to the label recommendations. Blood samples were collected before initial vaccination and 7 days after the booster.1 PUT CONFIDENCE INTO PRACTICE WITH NOBIVAC® LYME. LEARN MORE! Contact your Merck Animal Health sales representative or your distributor representative, today. Customer Service: 1-800-521-5767 (Monday–Friday, 9:00AM–6:00PM EST) Technical Services: 1-800-224-5318 (Monday–Friday, 9:00AM–7:00PM EST) Customer Service: 1-800-521-5767 (Monday–Friday, 9:00AM–6:00PM EST) Technical Services: 1-800-224-5318 (Monday–Friday, 9:00AM–7:00PM EST) References: 1. Dant JC, LaFleur RL, Callister SM, Stahl M, Sutton D, Tarpey I. Ability of antibodies induced by canine Lyme disease vaccines to kill viable spirochetes. Poster presented at: The ISCAID Symposium; October 16–19, 2016; Bristol, UK. 2. LaFleur RL, Dant JC, Wasmoen TL, et al. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin Vaccine lmmunol. 2009;16:253–259. Copyright © 2021 Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co., Inc. All rights reserved. US-NOV-210200011 297033.